Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop therapeutic treatments for degenerative ocular diseases. We are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While our drug platform is being tested on our lead indication, cataract; we are also in clinical trials for glaucoma and asteroid hyalosis.
